Particularly, tumor-derived EVs expressing PD-L1 can bind to PD-1 expressed on the surface of T cells, impairing T cell activation via anti-CD3 antibody ligation and DC antigen presentation [100]. This evidence concerns the gene PDCD1 and neoplasm.